梯瓦制药(TEVA.US)盘前大涨近13% Q3营收和调整后每股收益均超预期

Core Viewpoint - Teva Pharmaceuticals (TEVA.US) experienced a pre-market surge of nearly 13%, reaching $23.10, following a strong Q3 earnings report that exceeded market expectations [1] Financial Performance - Q3 revenue for Teva Pharmaceuticals was $4.48 billion, surpassing market expectations of $4.34 billion [1] - Adjusted earnings per share (EPS) for Q3 were $0.78, exceeding the market forecast of $0.68 [1] Future Guidance - The company projected its full-year revenue for fiscal year 2025 to be in the range of $16.8 billion to $17 billion, aligning closely with FactSet's estimate of $16.83 billion [1] - Teva raised its guidance for adjusted EPS for fiscal year 2025 from a range of $2.50-$2.60 to $2.55-$2.65, with analyst expectations at $2.58 [1]